<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Guide to buprenorphine for chronic pain - how it works, formulations, advantages, and considerations for pain treatment.">
    <meta name="keywords" content="buprenorphine, Butrans, Belbuca, buprenorphine pain, partial opioid agonist">
    <title>Buprenorphine | ChronicSoreness</title>
    <link rel="stylesheet" href="../css/styles.css">
</head>
<body>
    <header class="header"><nav class="nav-container"><div class="logo"><a href="../index.html"><span class="logo-icon">ðŸ’œ</span><span class="logo-text"><strong>Chronic</strong>Soreness</span></a></div><button class="mobile-menu-toggle" aria-label="Toggle menu"><span class="hamburger"></span></button><ul class="nav-menu"><li><a href="../conditions.html">Conditions</a></li><li><a href="../treatments.html">Treatments</a></li><li><a href="../medications.html">Medications</a></li><li><a href="../exercise.html">Exercise</a></li><li><a href="../nutrition.html">Nutrition</a></li><li><a href="../mental-health.html">Mental Health</a></li></ul></nav></header>
    <main id="main-content">
        <article class="page-header"><h1>Buprenorphine</h1><p>A unique opioid for chronic pain</p></article>
        <section class="content-section">
            <div class="container">
                <h2>What Is Buprenorphine?</h2>
                <p>Buprenorphine is a partial opioid agonist used for both pain treatment and opioid addiction. Its unique pharmacology offers potential advantages over traditional opioids, including a ceiling effect on respiratory depression and less euphoria. It's increasingly used for chronic pain management.<sup>1</sup></p>

                <h2>How It Works<sup>2</sup></h2>
                <ul>
                    <li>Partial mu-opioid receptor agonist</li>
                    <li>Kappa receptor antagonist</li>
                    <li>Has a "ceiling effect"</li>
                    <li>High receptor binding affinity</li>
                    <li>Long duration of action</li>
                </ul>

                <h2>Formulations for Pain</h2>
                <h3>Transdermal Patch (Butrans)</h3>
                <ul>
                    <li>Weekly patch</li>
                    <li>5, 7.5, 10, 15, 20 mcg/hour</li>
                    <li>For moderate to severe chronic pain</li>
                </ul>

                <h3>Buccal Film (Belbuca)</h3>
                <ul>
                    <li>Dissolves in cheek</li>
                    <li>Twice daily dosing</li>
                    <li>Various strengths</li>
                </ul>

                <h3>Sublingual/Buccal (Suboxone)</h3>
                <ul>
                    <li>Often combined with naloxone</li>
                    <li>Primarily for opioid use disorder</li>
                    <li>Sometimes used for pain</li>
                </ul>

                <h2>Potential Advantages<sup>3</sup></h2>
                <ul>
                    <li>Lower risk of respiratory depression</li>
                    <li>Less constipation than some opioids</li>
                    <li>May have less abuse potential</li>
                    <li>Stable blood levels (patch)</li>
                    <li>May help patients on high-dose opioids transition</li>
                    <li>Less immunosuppressive</li>
                </ul>

                <h2>Common Side Effects</h2>
                <ul>
                    <li>Nausea (especially starting)</li>
                    <li>Constipation</li>
                    <li>Headache</li>
                    <li>Dizziness</li>
                    <li>Drowsiness</li>
                    <li>Application site reactions (patch)</li>
                </ul>

                <h2>Important Considerations</h2>
                <ul>
                    <li>Schedule III controlled substance</li>
                    <li>Can precipitate withdrawal if started wrong</li>
                    <li>Special prescribing rules may apply</li>
                    <li>Drug interactions exist</li>
                    <li>Not easily reversed with naloxone</li>
                </ul>

                <h2>Who Might Consider</h2>
                <ul>
                    <li>Chronic pain requiring opioids</li>
                    <li>History of opioid misuse concerns</li>
                    <li>Desire to transition from other opioids</li>
                    <li>Poor response to other opioids</li>
                    <li>Medical conditions making other opioids risky</li>
                </ul>

                <h2>Starting Treatment</h2>
                <ul>
                    <li>Requires careful titration</li>
                    <li>May need opioid-free interval first</li>
                    <li>Start low, go slow</li>
                    <li>Provider experienced with buprenorphine helpful</li>
                </ul>

                <h2>References</h2>
                <ol>
                    <li>Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. <em>J Support Oncol</em>. 2012;10(6):209-219.</li>
                    <li>Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. <em>J Pain Res</em>. 2015;8:859-870.</li>
                    <li>Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. <em>Pain Pract</em>. 2010;10(5):428-450.</li>
                </ol>
            </div>
        </section>
    </main>
    <footer class="footer"><div class="container"><p class="disclaimer">The information provided is for educational purposes only and is not medical advice.</p><p class="copyright">Â© 2024 ChronicSoreness. All rights reserved.</p></div></footer>
    <script src="../js/main.js"></script>
</body>
</html>
